NCT02311543View on ClinicalTrials.gov

Impact of a Surgical Sealing Patch on Lymphatic Drainage After ALND for Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

March 18, 2015

Primary Completion Date

May 23, 2017

Study Completion Date

June 27, 2017

Conditions
Breast Cancer
Interventions
DRUG

TachoSil® patches

TachoSil® is a sterile, ready-to-use, absorbable surgical patch and consists of an equine collagen sponge coated with human fibrinogen and human thrombin.

Trial Locations (16)

1011

Centre Hospitalier Universitaire Vaudois CHUV, Lausanne

1211

Hôpitaux universitaires de Genève, Geneva

1951

CHVC Hôpital de Sion, Sion

3012

Brustzentrum, Klinik Engeried, Bern

4031

Universitätsspital Basel, Basel

5001

Kantonsspital Aarau, Aarau

5404

Kantonsspital Baden, Baden

6500

CSSI Bellinzona/Lugano, Ospedale San Giovanni, Bellinzona

7000

Kantonsspital Graubünden, Chur

8008

Brust-Zentrum Seefeld, Zurich

8063

Stadtspital Triemli, Zurich

8091

UniversitätsSpital Zürich, Klinik für Gynäkologie, Zurich

8401

Kantonsspital Winterthur, Brustzentrum, Winterthur

8501

Spital Thurgau AG, Brustzentrum, Frauenfeld

9006

Tumor- und Brustzentrum ZeTuP St. Gallen, Sankt Gallen

9007

Kantonsspital St. Gallen, Sankt Gallen

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER

NCT02311543 - Impact of a Surgical Sealing Patch on Lymphatic Drainage After ALND for Breast Cancer | Biotech Hunter | Biotech Hunter